In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
CRA Insights
From collaboration to court
June 4, 2014
Key contacts
![Gregory Bell | Expert Witness | Charles River Associates]()
Gregory K. BellGroup Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.com
Upcoming events
Asembia’s AXS26 Summit
CRA is a proud supporter of the conference where attendees span the full spectrum of the pharmacy and healthcare ecosystem, bringing together key...
GAR Live: Life Sciences
CRA is a proud sponsor of the first-ever GAR Live: Life Sciences, evolving from the much-loved Technology Disputes event to reflect the growing complexity and...